Biohope Welcomes Joshua Lee as Medical Director for US
Biohope is delighted to announce the appointment of Joshua Lee, MD, as the Medical Director for US. He has a diverse background in medical affairs and product launch in Cardiovascular, Nephrology, and Transplant therapeutic areas. With 14 years of experience, including AstraZeneca, Hansa Biopharma, and Immucor, he has worked in a variety of transplant roles in both pharmaceutical and biotech development bringing an essential component to our US development.
Josh holds a Medical Doctorate from Xavier University School of Medicine and previously was involved in kidney and lung cancer research at the National Cancer Institute. He has been involved in developing and implementing numerous clinical trials, generating publications, and has vast experience working with regulatory.
In his previous roles as medical director, he has published efforts in transplant equity and access, investigated gene expression’s role in preventing transplant rejection, and engaged with numerous stakeholders and key opinion leaders in the transplant community.
We welcome Josh to the Biohope Family! His passion for patients and advancing transplant will be a great asset to our goal of bringing IMBG to physicians and patients!
